XenoGesis has appointed Dr Rachel Hemsley as global head of business development. Rachel was previously the Senior Business Manager at UCL Business plc and has 12 years’ experience in business development involving early stage technology development, securing investment funding, licensing early stage healthcare technology and setting up new companies. Her experience spans across stem cell therapies, gene therapies, diagnostics and medical devices. She was also a director of an ocular gene therapy company, Athena Vision. Prior to this she worked in senior roles at the University of Leicester, including Intellectual Property Manager and Research and Business Development Officer.
